New Human Clinical Trial Supports Longvida Curcumin
By: Verdure Sciences
The promising results of this award-winning trial prompted researchers to conduct a follow-up study aimed at determining whether similar effects were evident following 12 weeks of taking Longvida. We are excited to share that the much-awaited results are in; according to Scholey et al., this follow-up study "confirm[s] that Longvida® improves aspects of mood and working memory in a healthy older cohort."2
The follow-up study was a double-blind, placebo-controlled, parallel-groups trial with eighty participants aged 50-80. The test subjects were randomized to receive 400 mg/day of Longvida® or a matching placebo. After a baseline assessment, results were measured at 4 and 12 weeks. Cognitive performance, measures of mood, cardiovascular function, and various other blood biomarkers were assessed. Longvida® was well-tolerated with no severe adverse effects.
Compared with placebo, the Longvida® group demonstrated a number of improvements. These included mood effects such as decreased tension, anger, confusion, and total mood disturbance at 4 weeks, lower fatigue scores at both 4 and 12 weeks. Working memory performance was also improved. The study leader Professor Andrew Scholey said "We should exercise some caution as the study hasn't yet undergone full peer review (although the conference abstracts were peer reviewed). Nevertheless the results of our second trial broadly support and extend the effects of the first study. We are currently further examining the effects of Longvida on hippocampal functioning."
Scholey et al. also concluded that Longvida® may hold promise for "alleviating cognitive decline in some populations."
† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.